Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 15, 2025

FcR Blocking Reagent, human

RRID:AB_2892112
Type: Antibody

Proper Citation

(Miltenyi Biotec Cat# 130-059-901, RRID:AB_2892112)

Antibody Information

URL: http://antibodyregistry.org/AB_2892112

Proper Citation: (Miltenyi Biotec Cat# 130-059-901, RRID:AB_2892112)

Target Antigen: FcR

Clonality: unknown

Comments: Applications: block unwanted binding of antibodies to human Fc receptor-expressing cells such as B cells, monocytes, and macrophages

Antibody Name: FcR Blocking Reagent, human

Description: This unknown targets FcR

Target Organism: human

Antibody ID: AB_2892112

Vendor: Miltenyi Biotec

Catalog Number: 130-059-901

Record Creation Time: 20231110T031632+0000

Record Last Update: 20240725T000941+0000

Ratings and Alerts

No rating or validation information has been found for FcR Blocking Reagent, human.

No alerts have been found for FcR Blocking Reagent, human.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 39 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Li Y, et al. (2024) Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. Cancer cell, 42(6), 985.

Rivera M, et al. (2024) Protocol for in vitro co-culture assay for rapid expansion of human T cell acute lymphoblastic leukemia. STAR protocols, 5(2), 103103.

Hirsch T, et al. (2024) IRF4 impedes human CD8 T cell function and promotes cell proliferation and PD-1 expression. Cell reports, 43(7), 114401.

Schmidt D, et al. (2024) Oncogenic Calreticulin Induces Immune Escape by Stimulating TGF? Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment. Cancer research, 84(18), 2985.

Ma S, et al. (2024) Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity. Cancer cell.

Schweiger P, et al. (2024) Functional Heterogeneity of Umbilical Cord Blood Monocyte-Derived Dendritic Cells. Journal of immunology (Baltimore, Md. : 1950), 213(2), 115.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy. Cell reports, 43(2), 113712.

Valeri E, et al. (2024) A novel STING variant triggers endothelial toxicity and SAVI disease. The Journal of experimental medicine, 221(9).

Dolton G, et al. (2023) Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell, 186(16), 3333.

Lu L, et al. (2023) STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells. Cell reports, 42(9), 113108.

Darrah PA, et al. (2023) Airway T cells are a correlate of i.v. Bacille Calmette-Guerin-mediated protection against tuberculosis in rhesus macaques. Cell host & microbe, 31(6),

962.

Herzfeldt AK, et al. (2023) Complementary CRISPR screen highlights the contrasting role of membrane-bound and soluble ICAM-1 in regulating antigen-specific tumor cell killing by cytotoxic T cells. eLife, 12.

Hsiao CC, et al. (2023) Osteopontin associates with brain TRM-cell transcriptome and compartmentalization in donors with and without multiple sclerosis. iScience, 26(1), 105785.

Lozano-Rabella M, et al. (2023) Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(12), 2250.

Laforêts F, et al. (2023) Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments. iScience, 26(4), 106514.

Alsaadi A, et al. (2023) Single-cell transcriptomics identifies a WNT7A-FZD5 signaling axis that maintains fallopian tube stem cells in patient-derived organoids. Cell reports, 42(11), 113354.

Foskolou IP, et al. (2023) The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic T cell function. Cell reports, 42(9), 113013.

Lameris R, et al. (2023) A bispecific T cell engager recruits both type 1 NKT and V?9V?2-T cells for the treatment of CD1d-expressing hematological malignancies. Cell reports. Medicine, 4(3), 100961.

Prokhnevska N, et al. (2023) CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity, 56(1), 107.

Krämer B, et al. (2023) Single-cell RNA sequencing identifies a population of human liver-type ILC1s. Cell reports, 42(1), 111937.